A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

Part of paid clinical trials in Ann Arbor, Michigan.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT07428044
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Non-Small Cell Lung Cancer
  • Non-Small Cell Lung Cancer Stage IIIA
  • Non-Small Cell Lung Cancer Stage IIIB
  • Non-small Cell Lung Cancer Stage II

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Trastuzumab Deruxtecan — DRUG
    Trastuzumab deruxtecan (T-DXd, fam-trastuzumab deruxtecan-nxki) is a novel HER2- targeting antibody-drug conjugate (ADC).

Study Details

The purpose of this study is to find out how many people with HER2-amplified or HER2-mutated non-small cell lung cancer (NSCLC) experience a decrease in tumor viability when they receive trastuzumab deruxtecan before routine surgery to remove tumors.

Key Dates

Start date
Feb 13, 2026
Status verified
Feb 2026
Primary completion
Feb 13, 2027
Completion
Feb 13, 2027

Study Design

Enrollment
14 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Participants with Non-Small Cell Lung Cancer
    Participants with Stage II, IIIA or IIIB Non-Small Cell Lung Cancer

Primary Outcome Measure

Major Pathologic Response/MPR Rate [ Time Frame: up to 1 year ]

Central Contacts

Locations (9)

FacilityCityStateZIPSite coordinators
University of Michigan (Data Collection Only)Ann ArborMichigan48109
Jules Lin, MD
734-936-8857
Mayo Clinic (Data Collection Only)RochesterMinnesota55905
Dennis Wigle, MD
507-538-3270
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)Basking RidgeNew Jersey07920
James Isbell, MD
212-639-6247
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)MiddletownNew Jersey07748
James Isbell, MD
212-639-6247
Memorial Sloan Kettering Bergen (Limited Protocol Activities)MontvaleNew Jersey07645
James Isbell, MD
212-639-6247
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)CommackNew York11725
James Isbell, MD
212-639-6247
Memorial Sloan Kettering Westchester (Limited Protocol Activities)HarrisonNew York10604
James Isbell, MD
212-639-6247
Memorial Sloan Kettering Cancer Center (All Protocol Activites)New YorkNew York10065
James Isbell, MD
212-639-6247
Memorial Sloan Kettering Nassau (Limited Protocol Activites)Rockville CentreNew York11553
James Isbell, MD
212-639-6247

Find similar trials in Ann Arbor, MI

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
University of Michigan (Data Collection Only)· Ann Arbor, MIMayo Clinic (Data Collection Only)· Rochester, MNMemorial Sloan Kettering Basking Ridge (Limited Protocol Activities)· Basking Ridge, NJMemorial Sloan Kettering Monmouth (Limited Protocol Activities)· Middletown, NJMemorial Sloan Kettering Bergen (Limited Protocol Activities)· Montvale, NJMemorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)· Commack, NY

Related Studies